Insights into comparative molecular docking study of selected novel thiophene derivative vs standard anti-tubercular drugs against Mycobacterium tuberculosis target enzymes

Today, Mycobacterium Tuberculosis (TB) is a major global public threat. The development of Multidrug-resistant tuberculosis (MDRTB), Extreme drug-resistant tuberculosis (XDR-TB) and totally drug-resistant strains of tuberculosis (TDRTB) and co-infection with HIV leads to an urgent need for the development of new anti tb agents. Hence, this research highlights the drug design and screening of few thiophene derivatives against specific target enzymes like L, d transpeptidase-2, the enoyl-acyl carrier protein reductase (InhA) and Glutamine synthetase-1 of Mycobacterium tuberculosis. The molecular docking studies of the designed thiophene derivatives against selected Mtb target enzymes were carried out by the Auto dock® docking software. The current study gives insights into the development of newer anti-tubercular agents against resistant strains of mtb with lesser side effects.